Curated news and analysis on clinical trials, drug approvals, and medical research.
A multicenter EFFORT Trial published in The Lancet Infectious Diseases found that 7-day high-dose primaquine and single-dose tafenoquine significantly reduced P. vivax malaria recurrence compared to the standard 14-day low-dose primaquine regimen. The trial, conducted across Ethiopia, Pakistan, Indonesia, and Cambodia, supports WHO guidelines and potential geographic expansion of tafenoquine use.
A case report describes eight-and-a-half syndrome in a 71-year-old man with hypertension and ischemic heart disease who presented with acute neurological deficits. MRI revealed an acute pontine infarction causing the characteristic triad of horizontal gaze palsy, internuclear ophthalmoplegia, and facial weakness.
The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.
Police in Portland, Maine, issued a public safety alert after 7 suspected overdoses in under 20 hours, while Huntington, WV, police seized over 900 fentanyl-laced tablets disguised as cartoon characters. Both departments warned of dangerous fentanyl contamination in the drug supply.
New rankings from WIPR and IAM Patent 1000 recognize top US patent firms and lawyers, highlighting expertise in pharmaceutical litigation, tech disputes, and strategic portfolio management amid shifting PTAB procedures and rising NPE campaigns in life sciences.
British Columbia has approved the $3-billion expansion of the Red Chris copper-gold mine, a key step for Newmont's final investment decision later this year. The project will extend the mine's life by over a decade and increase Canada's annual copper production by more than 15%.
The Fonds pour l'Innovation et le Futur de Genève (FIF) has awarded funding to six Geneva-based startups across two rounds, including Backbone, Crìa Technologies, Scenario X, Flottando, Axy, and Nose Switzerland, supporting innovations in AI, quantum computing, fleet management, and life sciences.
Multiple studies confirm high effectiveness of key antimalarial drugs in Indonesia, Ethiopia, and for malaria prevention in HIV-positive pregnancies. Research shows DHA-PPQ, artemether-lumefantrine, and other treatments remain well-tolerated with no delayed parasite clearance. Findings support continued use of current treatment policies while emphasizing the need for ongoing monitoring.
A phase IIb trial demonstrated that low-dose IL-2 therapy produced dose-dependent improvements in SLE patients, with 69.7% achieving SRI-4 response at the highest dose versus 23.5% on placebo. A separate systematic review found IL-17 inhibitors remain potential SLE treatment options, though efficacy data are limited.
Swissmedic has authorized three orphan drugs for rare diseases: Breyanzi for mantle cell lymphoma, Alhemo for haemophilia A and B, and Ekterly for hereditary angioedema. The decisions include a new indication extension for Breyanzi, an expanded indication for Alhemo, and the initial authorization of Ekterly as part of a joint international regulatory initiative.
Regeneron announced FDA and EMA review acceptance for cemdisiran in generalized myasthenia gravis and FDA priority review acceptance for garetosmab in fibrodysplasia ossificans progressiva. The garetosmab BLA is supported by Phase 3 OPTIMA trial data showing 94% and 90% reductions in new bone lesions.
Eledon Pharmaceuticals reported positive long-term Phase 2 BESTOW trial results for tegoprubart in kidney transplant, showing sustained kidney function benefits and improved patient outcomes versus tacrolimus. The company outlined plans for a Phase 3 registrational trial and seeks an FDA meeting in early 2027. Safety data indicated lower adverse event rates with tegoprubart.
ChemT Biotechnology closed a $4 million seed round led by Wavemaker Ventures to advance its AI-driven biomanufacturing platform. The company's CelMo™ platform demonstrated a 50% increase in antibody output in CHO cells. ChemT plans to expand its technology to stem cells, NK cells, and HEK cells.
China has approved the world's first CAR-T cell therapy for solid tumors, specifically for stomach cancer, developed by CARsgen Therapeutics. Meanwhile, the WVU Cancer Institute has conducted the first-ever use of a subcutaneous formulation of blinatumomab to achieve remission in a patient with ultra-rare mixed phenotype acute leukemia.
A Massachusetts judge allowed key prosecution evidence, including autopsy photos and a 911 call, in the murder trial of Lindsay Clancy, accused of killing her three children in 2023. The judge denied a defense request for a bifurcated trial. The trial is set to begin July 20.
Research estimates 300 million people worldwide live with rare diseases, yet only 5% of conditions have approved treatments. Patients face diagnostic delays of 4.7 to 8 years, with emerging AI and machine learning tools showing promise in accelerating diagnosis and drug development.
In Australia, 19 women are diagnosed daily with gynaecological cancer, and experts say late detection is the primary issue. Ovarian cancer is often caught at advanced stages, while endometrial cancer deaths are rising. Personal stories underscore the need for early symptom awareness.
New clinical data for ANKTIVA immunotherapy in lung cancer, a study on EBV-driven resistance via ADAR1 RNA editing, and research on microbiome metabolites modulating immunotherapy response were presented at major conferences and in recent publications.
Cantargia reported full year 2025 financial results with net sales of SEK 316.7 million and cash of SEK 281.8 million. The company secured a SEK 124 million financing package to advance clinical development of nadunolimab, including a phase Ib study combining it with a RAS inhibitor in pancreatic cancer.
The FDA now allows "no artificial colors" labeling claims for foods without FD&C-certified synthetic colors, part of federal efforts to transition away from petroleum-based dyes. The agency approved beetroot red and expanded spirulina extract uses while initiating a safety review of preservative BHA.
